Over the past several years, a number of RCTs have been conducted to investigate the efficacy of adding vandetanib, a once-daily oral anticancer agent that targets VEGFR, EGFR and RET (rearranged during transfection) signaling [7], [8], to standard chemotherapy in patients with advanced NSCLC, but with diverse results. The gene discussed is RET; the disease is non-small cell lung carcinoma.